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Platelet-derived growth factor plays a critical role to convert
bone marrow cells into glomerular mesangial-like cells.
Background. Despite increasing interest in bone marrow–
derived stem cells, little is known about critical factors that de-
termine their fates both in vitro and in vivo. Recently, we have
reported that bone marrow is a reservoir for glomerular mesan-
gial cells in rats. To find a key factor responsible for the differ-
entiation of bone marrow–derived cells into mesangial cells, we
established a new culture system of rat bone marrow, which is
based on serial replating and differential attachment to collagen
types I and IV.
Methods. Bone marrow cells that did not adhere to collagen
type I within 24 hours were transferred to collagen type IV–
coated dishes. Then, the cells attached to collagen type IV in the
following 24 hours were maintained in the presence of 2% horse
serum, 200 ng/mL of platelet-derived growth factor (PDGF)-
BB, and 1 lmol/L of all-trans retinoic acid. In vivo effect of
PDGF-B was also examined by introducing human PDGF-B
gene into glomeruli.
Results. After cultivation under the above condition for
7 days, approximately 14% of cells expressed Thy-1 and
desmin, both of which are markers for rat mesangial cells.
Thy-1++/desmin+ cells were stellate-shaped, and contracted in
response to angiotensin II. When human PDGF-B gene was
overexpressed in the glomeruli of chimeric rats whose bone
marrow was transplanted from enhanced green florescent pro-
tein (EGFP) transgenic rats, the number of EGFP+ mesangial
cells increased. This effect was canceled by prior introduction of
a neutralizing molecule that is composed of PDGF receptor-b
ligand binding site and IgG-Fc.
Conclusion. These results indicate that PDGF-B plays a criti-
cal role to direct bone marrow–derived cells toward mesangial-
like cells both in vitro and in vivo.
Mesangial cells, often considered to be equivalent to
pericytes, provide physical support for the glomerular
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capillary lumen of the kidney. These cells are located in
the intraglomerular structure, extend out into the jux-
taglomerular zone, and show a low rate of cell divi-
sion in normal mature glomeruli [1]. Since the normal
glomerular capillary is essential to keep efficient ultrafil-
tration of the plasma, loss of mesangial cells due to patho-
logic conditions such as glomerulonephritis and diabetic
nephropathy leads to impaired renal function. The ex-
act developmental origin of mesangial cells is unknown,
but it is generally accepted that mesangial cells come
from the mesenchymal blastema or metanephric mes-
enchyme containing immature mesenchymal cells. Alter-
natively, mesangial cells may be derived from vascular
pericytes, vascular smooth muscle cells, or myofibroblasts
of invading vasculatures during the nephrogenesis [2, 3].
It is noteworthy that mesangial cells are not found in
avascular glomeruli of transfilter-induced mesenchymes,
suggesting that vasculature or blood circulation commu-
nicating with other tissues such as bone marrow may be
crucial for the establishment of the mesangial structure
[4].
Bone marrow–derived cells, whose contribution to the
healing process of glomerular diseases remains unknown,
attract great interest because of their therapeutic poten-
tials. It has been established that mesenchymal stem cells,
which are derived from bone marrow, have a potential to
differentiate into different lineages in response to differ-
ent environments [5, 6]. By tagging bone marrow–derived
cells with enhanced green fluorescent protein (EGFP),
we have recently reported that the adult bone marrow
carries stem cells for glomerular mesangial cells [7, 8]. It
can be expected that the mesangial stem cells share sev-
eral basic properties with stem cells differentiating into
other types of cells [9]. All stem cells need to proliferate in
response to tissue damage, which should be promoted by
the release of mitogens from injured tissue components,
or by relief from inhibitors normally produced by healthy
tissues. Subsequently, stem cells are engaged in the
differentiation process. There is considerable evidence
that restricted microenvironments, including types of
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growth factors and cell-cell interactions, influence fates of
multipotent stem cells and give them the competence to
contribute to more specific lineages. So far, however, lit-
tle is known about the events regulating the acquisition
of the competence that is required for bone marrow–
derived stem cells to differentiate into nonhematopoi-
etic cells. Since nonhematopoietic stem cells in the bone
marrow are spatially segregated from target organs that
the stem cells contribute to build up or to regenerate, it
is likely that the target organs secrete factors acting on
nonhematopoietic stem cells.
The close relationship between mesangial cells and
platelet-derived growth factor (PDGF)-B has been de-
scribed from many points of view. PDGF-B is produced
physiologically or pathologically by several renal cell
types in vivo, which include mesangial, glomerular, and
tubular epithelial, and endothelial cells in addition to
infiltrating macrophages and platelets. PDGF-B, which
mediates mitogenic and chemotactic effects on many
mesenchymal types of cells, including vascular smooth
muscle cells, fibroblasts, and mesangial cells in vitro
[10], plays a pivotal role in the establishment of ma-
ture glomeruli that are structurally supported by mesan-
gial cells. Mice deficient in PDGF-B or PDGF receptor
(PDGFR)-b have primitive glomerular capillaries with
glomerular epithelial cells and endothelial cells, but do
not form the normal mesangium that is composed of
mesangial cells and matrix proteins [11, 12]. Stromal cells
surrounding the vascular cleft of the S-shaped body are
likely to be the developmental precursor of mesangial
cells because they express PDGFR-b [13, 14]. In our
previous experiment, mesangiolysis evoked by the ad-
ministration of anti-Thy-1 antibody was the key event to
integrate bone marrow–derived cells as mesangial cells
[8]. Several lines of evidence show that PDGF-B is
responsible for the mesangial proliferation in this ex-
perimental glomerulonephritis. First, the expression of
PDGF-B is up-regulated in this disease model [15].
Second, both the administration of PDGF-B neutral-
izing antibody [16] or oligonucleotide aptamers [17]
and the overexpression of a chimeric molecule that is
composed of the ligand binding site of PDGFR-b and
IgG-Fc portion [18] suppress the proliferation of mesan-
gial cells and inhibit the overproduction of extracellular
matrix. By contrast, PDGF, when exogenously adminis-
tered or overexpressed in glomeruli, induces mesangial
proliferation [19, 20]. Moreover, human glomerular dis-
eases with mesangial proliferation are accompanied by
the up-regulation of PDGFRs [21, 22].
Here, by using a newly established in vitro system,
we confirmed our previous in vivo results that the adult
bone marrow carries stem cells for mesangial cells. In
addition, we have identified that PDGF-B plays a key
role for the recruitment and/or differentiation of bone
marrow–derived mesangial stem cells both in vitro and in
vivo.
METHODS
Animals
Wild-type Sprague-Dawley rats and transgenic
Sprague-Dawley rats that express EGFP throughout
their bodies (EGFP rat) were used [7, 8]. All rats weighing
150 to 180 g, anesthetized by intraperitoneal administra-
tion of pentobarbital, were subjected to the experiments.
Procedures for the present study were approved by
the Animal Committee at Osaka University School
of Medicine.
Preparation of bone marrow and bone
marrow transplantation
For culture, bone marrow cells were prepared from
wild type male Sprague-Dawley rats [7, 8]. To estab-
lish bone marrow chimeric rats, bone marrow cells were
harvested from male EGFP rats and were transplanted
into wild-type female Sprague-Dawley rats as described
previously [7, 8].
Cell culture
Freshly isolated bone marrow cells were resuspended
in the growth medium [Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco, Invitrogen, Carlsbad, CA,
USA)] supplemented with 10% fetal calf serum (FCS)
(Gibco), 10% horse serum (Gibco), 0.5% chick em-
bryo extract (Gibco), and 4% penicillin/streptomycin),
and were seeded on collagen type I–coated dishes (BD
PharMingen, San Diego, CA, USA) at a density of 5 × 106
cells/mL. Then, the cells were maintained in the growth
medium at 5% CO2 and 37◦C. After 24 hours, the cells
that did not adhere to collagen type I were transferred to
fresh collagen type IV–coated dishes (BD PharMingen).
The supernatant containing cells that did not adhere to
collagen type IV within another 24 hours were discarded
by changing the medium. The cells that attached to
collagen type IV were maintained for further 7 days
in the growth medium or the differentiation medium
[DMEM supplemented with 2% horse serum, 200 ng/mL
rat PDGF-BB (R&D Systems, Minneapolis, MN, USA),
1 lmol/L all-trans retinoic acid (Sigma, Deisenhofen,
Germany), and 4% penicillin/streptomycin]. The
medium was changed every 3 days. Rat mesangial cells
were obtained from 6-week-old Sprague-Dawley rats
by the sieving method and were cultured in RPMI1640
(Sigma) supplemented with 20% FCS as described
previously [8].
Immunocytochemistry and flow cytometric analysis
For immunocytochemistry, the culture cells were
replated on chamber slides (Nunc, Naperville, IL, USA)
and were fixed with ice-cold methanol for 5 minutes.
Signals were detected by using fluorescein isothio-
cyanate (FITC)- or Texas Red-conjugated secondary
antibody (Vector Laboratories, Burlingame, CA, USA).
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Primary antibodies except for mouse antirat Thy-1
monoclonal antibody (ox-7) were obtained from com-
mercial sources: antidesmin (BioScience Products,
Emmenbruecke, Switzerland), antipancytokeratin
(Sigma), anti-RECA1 (CosmoBio, Tokyo, Japan),
anti-Factor VIII (Neomarkers, Fremont, CA, USA),
anticellular fibronectin (Abcam, Cambridge, UK),
anti-Cd11b (Oxford Biotechnology, Oxford, UK), and
anti-a-smooth muscle actin (Sigma). Ox-7 was provided
by Dr. Seiichi Matsuo (Nagoya University, Nagoya,
Japan). For flow cytometric analysis, adherent bone
marrow cells on collagen types I or IV were rinsed
with phosphate-buffered saline (PBS) twice and treated
with 0.05% trypsin/0.02% ethylenediaminetetraacetic
acid (EDTA) at room temperature. After 1 minute, the
cells were dislodged by vigorous tapping the culture
dishes, and trypsin was immediately neutralized with
DMEM supplemented with 10% FCS. The dislodged
cells were dispersed as possible by pipetting up and
down, and clumps were removed by passing through
50 lm nylon mesh. It took more than 5 minutes to
dislodge and disperse mesangial cells by treatment of
0.05% trypsin/0.02% EDTA at 37◦C. To stain Thy-1
antigen, cells resuspended in PBS containing 2% FCS
and 2% normal rat serum were reacted with anti-Thy-1
monoclonal antibody on ice for 1 hour. After washed in
PBS containing 2% FCS and 2% normal rat serum three
times, the cells were incubated with FITC-conjugated
secondary antibody for 30 minutes on ice in the dark.
Next, after washed in PBS, the cells were fixed in 4%
paraformaldehyde/PBS on ice for 20 minutes in the dark
and were permeabilized with 0.1% NP-40/1% bovine
serum albumin(BSA)/PBS. Then, the cells were reacted
with antidesmin polyclonal antibody on ice for 1 hour
in the dark, which was followed by the incubation with
phycoerythrin-conjugated secondary antibody and sub-
sequent washes. Flow cytometric analysis was performed
by using a FACSVantage SE (BD PharMingen).
Angiotensin II treatment
The cells were trypsinized and were seeded at a den-
sity of 1 to 10 × 103 per well in 24-well poly-L-lysine-
coated plates. After 24 hours, the medium was replaced
by Hanks’ balanced salt solution supplemented with 10
mmol/L Hepes/NaOH (pH 7.4). Under a VHS video
recording system, the cells were stimulated with 10
nmol/L of angiotensin II (Sigma) in the presence or ab-
sence of 1 nmol/L CV-11974 [an angiotensin II type 1
(AT1) receptor antagonist] (Takeda Chemical Industries,
Osaka, Japan). Captured images were converted to digi-
tal files by using video editing software (Adobe Premiere,
Adobe System, Inc., San Jose, CA, USA).
Overexpression of PDGF-B in the kidney
Three weeks after the bone marrow transplanta-
tion, 200 lg of the plasmid pcDNA3 harboring human
PDGF-B gene or the plasmid vector alone was injected
into the left kidney via the left renal artery of the bone
marrow chimeric rats. Immediately, the gene was intro-
duced into glomeruli by using an electroporation tech-
nique [23]. This technique introduces an exogenous gene
mainly into glomerular mesangial cells [23]. Neutraliza-
tion of the effect of PDGF-B in rat glomeruli was per-
formed as described previously [18]. Briefly, 200 lg of
pCAGGS-PDGFR/Fc coding a hybrid molecule com-
posed of PDGFR-b ligand binding site and IgG-Fc was
transfected into the skeletal muscle of the right hindlimb
of PDGF-B-transfected rats 24 hours before the trans-
fection of PDGF-B by an electroporation technique [18].
One-week after the introduction of human PDGF-B
gene, rats were thoroughly perfused with PBS followed
by 10% buffered formalin via the abdominal aorta, and
the kidneys were fixed for 3 hours in 10% buffered
formalin at 4◦C. The tissues were processed by using
antibodies as follows: rabbit antidesmin polyclonal anti-
body, mouse antirat monocyte/macrophage monoclonal
antibody (ED1)(Serotec, Ltd., Oxford, England), rab-
bit anti-green fluorescent protein (GFP) polyclonal an-
tibody (Molecular Probe, Inc., Eugene, OR, USA), and
corresponding secondary antibodies (Vector Laborato-
ries, Burlingame, CA). Under a fluorescent microscope
with the filter for Texas Red, glomeruli could be identi-
fied by observing faint background fluorescence even in
the absence of Thy-1 staining.
Immunoblot analysis
Lower poles of the kidneys were homogenized in 2 vol-
ume of homogenizing buffer [20 mmol/L Tris HCl (pH
8.0)/140 mmol/L NaCl/1 mmol/L EDTA/5 mmol/L
dithiothreitol (DTT)/protease inhibitor cocktail
(Complete MiniTM) (Roche Diagnostics, Mannheim,
Germany). One hundred micrograms of the protein
extract that was prepared from PDGF-transfected
kidneys or control kidneys was subjected to immunoblot
analysis by using antihuman PDGF-B polyclonal anti-
body (Ab-1) (R&D Systems). Signals were detected by
using horseradish peroxidase-conjugated antirabbit IgG
antibody and RenaissanceTM chemiluminescence system
(NEN, Boston, MA, USA).
RESULTS
Morphologic change of bone marrow cells in vitro
Crude preparation of bone marrow cells contains
various types of cells, including marrow stromal cells,
mesenchymal stem cells, and blood cells as well as
hematopoietic stem cells. In order to roughly enrich im-
mature stem cells from other types of cells, we followed
and modified a method that is useful to enrich immature
mesenchymal cells that are derived from skeletal mus-
cle [24]. The growth medium, originally defined in that
18 Suzuki et al: Conversion of bone marrow cells into mesangial-like cells
Fig. 1. Morphology of bone marrow cells in vitro. Rat bone marrow–
derived cells were cultured as described in the Methods section. Then,
the cells were fixed in ice-cold methanol and were stained with Giemsa.
Light microscopic images are shown (×400). (A) Cells on collagen type
I in the growth medium. (B) Cells on collagen type IV in the growth
medium. (C) Cells on collagen type IV in the differentiation medium.
study, is capable of preserving the pluripotency of mouse
skeletal muscle-derived mesenchymal stem cells for days
[24].
In our experiments, 0.5% to 5% of bone marrow cells
adhered to collagen type I, which depended on the prepa-
ration. The cells uniformly showed spindle-shape that was
reminiscent of fibroblasts, proliferated fast in the growth
medium, and created very dense culture (Fig. 1A). Next,
the cells that did not adhere to collagen type I within the
initial 24 hours were transferred to collagen type IV. Ap-
proximately, 0.2% to 3% of the cells adhered to collagen
type IV in the following 24 hours, and were maintained in
the growth or the differentiation medium. Although the
cells on collagen type IV proliferated relatively slow in
the growth medium when compared to the cells on col-
lagen type I, both cells looked alike (Fig. 1A and B). We
further focused our efforts on the cells that did not adhere
to collagen type I but later adhered to collagen type IV,
because stem cells for mesangial cells must be less adher-
ent to reach the kidney via the circulation. When main-
tained in the differentiation medium, cells on collagen
type IV ceased proliferation and subsequently changed
into a wide range of shapes from spindle to stellate and
from small to large (Fig. 1C). During the culture in the
differentiation medium, a considerable number of cells
fell into apoptosis and then detached. At the end of
7-day culture in the differentiation medium, simple calcu-
lation revealed that approximately 0.07% to 0.3% of the
original bone marrow cells remained in the dishes. How-
ever, it was difficult to estimate how many numbers of or
what types of cells contributed to the population shown
in Figure 1C because the whole process is composed of
the mixture of proliferation, apoptosis, and differentia-
tion. All-trans retinoic acid induced extensive apoptosis
of cells on collagen type IV when PDGF-BB was omit-
ted (data not shown). By contrast, PDGF-BB alone was
less effective to produce stellate cells, which suggests the
supportive role of all-trans retinoic acid.
Expression of Thy-1 and desmin in cultured bone
marrow cells
Since stellate cells in the differentiation medium
were reminiscent of mesangial cells, the expression of
Thy-1 and desmin was examined. Both molecules are
well-established markers for rat mesangial cells in vitro
[25, 26]. Flow cytometric analysis showed several distinct
populations regarding the expression level of Thy-1 anti-
gen (Fig. 2). Two of them, Thy-1–negative (Thy-1−) and
Thy-1–weakly positive (Thy-1+) populations, were evi-
dent in the histogram of freshly isolated bone marrow
cells and bone marrow cells that did not adhere to col-
lagen type I (Fig. 2A and B). Another distinct group ex-
pressing Thy-1 antigen strongly (Thy-1++) was seen in the
cells that did not attach to collagen type I within 24 hours
yet attached to collagen type IV in the following 24 hours
(Fig. 2C and D). It is noteworthy that the culture in the
differentiation medium produced more number of cells
with stronger expression of Thy-1 than that in the growth
medium. The increase of Thy-1++ cells was accompa-
nied by the reciprocal decrease of Thy-1− or Thy-1+ cells,
which suggested that Thy-1++ cells were converted from
Thy-1− and/or Thy-1+ cells. Alternatively, the differen-
tiation medium might support the preferential growth
of Thy-1++ cells. Forward scatter analysis showed that
Thy-1+/++ cells were heterologous. Since a value of for-
ward scatter roughly correlates with the size of a cell be-
ing analyzed, Thy-1++ cells seemed to contain cells larger
than Thy-1+ and Thy-1− cells (Fig. 2F to I). Even cultured
mesangial cells (passage 3) comprised heterologous types
of cells in terms both of Thy-1 expression and of forward
scatter (Fig. 2E and J). Because trypsinization was un-
avoidable to disperse cells before flow cytometric analysis
and because cultured mesangial cells were more adhesive
and cloggier than the cells on collagen type IV in the dif-
ferentiation medium, we could not exclude a possibility
that trypsinization differently affected the preservation of
surface proteins such as Thy-1 and potentially intracellu-
lar proteins such as desmin. At least, however, digestion
time for the cells from 2 minutes to 7 minutes gave essen-
tially identical results (data not shown).
While 50 ng/mL of PDGF-BB was enough to protect
cells from retinoic acid–induced apoptosis but not to pro-
duce Thy-1++ cells, the effect of 500 ng/mL of PDGF-BB
was indistinguishable from that of 200 ng/mL of PDGF-
BB as long as flow cytometric analysis was performed
(data not shown). Therefore, there might be a critical
concentration between 50 and 200 ng/mL.
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Fig. 2. Phenotypic changes of bone marrow
culture. Rat bone marrow–derived cells and
rat mesangial cells were stained with anti-
Thy-1 antibody and were subjected to flow-
cytometry. (A and F) Freshly isolated bone
marrow cells. (B and G) Bone marrow cells
that did not adhere to collagen type I within
24 hours (before replating to collagen type
IV–coated dishes). (C and H) Bone marrow
cells that adhered to collagen type IV (after
7-day culture in the growth medium). (D and
I) Bone marrow cells that adhered to collagen
type IV (after 7-day culture in the differenti-
ation medium). (E and J) Rat mesangial cells
[cultured in RPMI 1640/20%fetal calf serum
(FCS), passage 3].
Fresh bone marrow preparation was completely
desmin-negative, and only a small portion of cells that did
not adhere to collagen type I within 24 hours expressed
desmin weakly (Fig. 3A and B). In contrast, a significant
number of the cells that attached to collagen type IV
clearly expressed desmin (Fig. 3C and D). Among them,
the expression level of desmin or Thy-1 was diverse, and
most of Thy-1+ or Thy-1++ cells did not express desmin
(Fig. 3C and D). In the differentiation medium, however,
approximately 14% of the cells on collagen type IV ex-
pressed Thy-1 and desmin strongly (Thy-1+/++/desmin+).
This number was remarkably higher than the number of
cells under the growth condition. In case of mesangial
cells (passage 3), 45% of the cells expressed Thy-1 and
desmin simultaneously (Fig. 3E). Again, these numbers
might be underestimated because trypsinization would
compromise the antigens.
Expression of Thy-1 and desmin was confirmed by im-
munocytochemistry (Fig. 4A). The expression level of
Thy-1 was considerably diverse as shown in Figures 2 and
3. Here, we arbitrarily classified the cells into three classes
again: Thy-1−, Thy-1+, and Thy-1++. Thy-1++desmin+
cells were mostly flat and stellate. These cells were hardly
found in the cells on collagen type I or in the cells on col-
lagen type IV in the growth medium (data not shown).
In consistence with flow cytometric analysis, Thy-1+/++
cells were larger than Thy-1− cells.
To further characterize the cells in the differentiation
medium, expression of pancytokeratin, RECA1, factor
VIII, cellular fibronectin, Cd11b, or ∝-smooth muscle
actin was tested with mesangial cells as the control
(Fig. 4B). Neither epithelial cells nor endothelial cells
Fig. 3. Expression of Thy-1 and desmin. Cultured bone marrow–
derived cells and rat mesangial cells were subjected to flow cytomet-
ric analysis after stained with anti-Thy-1 antibody and anti-desmin an-
tibody. The percentage of cells expressing both Thy-1 and desmin is
shown in each panel. (A) Freshly isolated bone marrow cells. (B) Bone
marrow cells that did not adhere to collagen type I within 24 hours (be-
fore replating to collagen type IV–coated dishes). (C) Bone marrow
cells that adhered to collagen type IV (after 7-day culture in the growth
medium). (D) Bone marrow cells that adhered to collagen type IV (af-
ter 7-day culture in the differentiation medium). (E) Rat mesangial cells
[cultured in RPMI 1640/20% fetal calf serum (FCS), passage 3].
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Fig. 4. Mesangial properties of differenti-
ated cells. (A) Rat bone marrow–derived cells
that were cultured on collagen type IV in
the differentiation medium for 7 days were
stained with anti-Thy-1 antibody and anti-
desmin antibody. Immunocytochemical im-
ages are shown. (A) Panel a is Thy-1 (×200);
panel b is desmin (×200); panel c is the
merge (×200); and panel d is a larger im-
age of the Thy-1++desmin+ cell (×400). Var-
ious types of cells such as Thy-1+desmin-
cell (yellow arrowhead), Thy-1−desmin+ cell
(white arrowhead), and Thy-1++desmin+ cell
(white arrow) are seen. (B) Rat bone marrow–
derived cells and rat mesangial cells (passage
3) were stained with various antibodies (origi-
nal magnification ×200). Panels 1 to 6 are cul-
tured mesangial cells; panels 7 to 12 are bone
marrow–derived cells on collagen type IV in
the differentiation medium for 7 days. Panels
1 and 7 are pancytokeratin; panels 2 and 8 are
RECA1; panels 3 and 9 are factor VIII; pan-
els 4 and 10 are cellular fibronectin; panels 5
and 11 are Cd11b; and panels 6 and 12 are
∝-smooth muscle actin. (C) Time-lapse im-
ages of a cell that contracts in response to an-
giotensin II. Bone marrow–derived cells that
adhered to collagen type IV were cultured in
the differentiation medium for 7 days. Then,
the cells were replated and then exposed to
10 nmol/L of angiotensin II. Representative
sequential images are shown (total recording
time was 1 minute and 27 seconds, Quick-
Time movie is available upon request). Time
is indicated as min:second. Angiotensin II was
added at 00:10.
were found in the cells as long as determined by the ex-
pression of pancytokeratin (Fig. 4B1 and B7), RECA1
(Fig. 4B2 and B8), and factor VIII (Fig. 4B3 and B9).
Although a small number of round Cd11b-positive leuko-
cytes existed (Fig. 4B5 and B11), they were rather remark-
able in the mesangial culture (passage 3). The stellate
cells in the differentiation medium clearly expressed cel-
lular fibronectin (Fig. 4B4 and B10) and a-smooth muscle
actin (Fig. 4B6 and B12), which highly resembled cultured
mesangial cells.
Contraction of cultured bone marrow cells in response
to angiotensin II
Mesangial cells in vitro have some characteristics that
include stellate shape in culture and contraction in re-
sponse to vasoactive peptides such as angiotensin II and
vasopressin [27]. As shown in Figure 4C, angiotensin
II induced dramatic contraction of the stellate cells.
AT1-receptor antagonist, CV-11974, completely abol-
ished this effect of angiotensin II, and vehicle alone had
no effect on the cells (data not shown). Following the
video recording, the stellate cells that contracted in re-
sponse to angiotensin II were fixed and stained. Finally,
they were confirmed to express Thy-1++ or Thy-1+ and
desmin (data not shown).
In vivo differentiation of bone marrow cells
into mesangial cells
Our in vitro experiments revealed that PDGF-BB
might play a role to convert bone marrow–derived cells
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Fig. 5. Effects of the overexpression of
human platelet-derived growth factor-B
(PDGF-B) on glomeruli of chimeric rats.
(A) Immunoblot analysis is shown. Protein
extract obtained from mock-transfected kid-
neys or human PDGF-B–transfected kidneys
was subjected to immunoblot analysis to see
the expression of human PDGF-B. The arrow
indicates PDGF-B. (B) Paraffin sections were
stained with anti-GFP antibody (brown).
Then, the sections were counterstained with
hematoxylin-eosin (×400). PDGF(−) is
mock-transfected kidneys (vector alone);
PDGF(+) is PDGF-transfected kidneys.
The inset shows representative brown
cells with a higher magnification, which
is indicated by yellow arrows. (C) Fixed
frozen sections were stained with anti-Thy-1
antibody (red). Enhanced green florescent
protein (EGFP) provides green (×400).
Bone marrow–derived Thy-1–positive cells
provide yellow color. Representative cells are
indicated by yellow arrowheads. PDGF(−)
is mock-transfected kidneys (vector alone);
PDGF(+) is PDGF-transfected kidneys. (D
and E) Fixed frozen sections prepared from
PDGF-transfected kidneys were stained
with anti-monocyte/macrophage (ED1)
antibody or anti-CD45 antibody followed by
Texas Red-conjugated secondary antibody
(red). EGFP provides green. Glomeruli
are surrounded by gray arrowheads for the
reference. (D), ED1; (E), CD45. White
arrowhead and arrow indicate ED1+EGFP+
cell and CD45+EGFP+ cell, respectively
(×400).
Fig. 7. Effect of the neutralization of human
platelet-derived growth factor-B (PDGF-B)
frozen sections were prepared from PDGF-
transfected kidney with or without the neu-
tralization by PDGFR/Fc and were stained
with anti-Thy-1 antibody (red). Representa-
tive images are shown. (A) Human PDGF-
B–transfected kidneys. (B) Human PDGF-B–
transfected kidneys with the neutralization by
PDGFR/Fc (×400).
into mesangial cells or at least into cells with mesangial
properties. In order to examine the relevance of PDGF-B
in vivo, human PDGF-B gene was transiently overex-
pressed in the left kidney of bone marrow chimeric rats
by using the electroporation technique. This technique al-
lows us to introduce a gene of interest mainly in glomeruli
when the gene is administered via the renal artery [23].
Since normal glomeruli express collagen type IV, PDGF-
transfected glomeruli would produce a condition at least
partly mimicking the in vitro culture condition in the
differentiation medium. One week after the electropo-
ration, proliferation of mesangial cells in response to
overexpressed PDGF-B was compatible with our pre-
vious report that exogenous PDGF-B gene induced
mesangial proliferation when transfected to glomeruli
by hemagglutinating virus of Japan (HVJ) liposome
(Fig. 5B)[20]. The increase of bone marrow–derived
Thy-1+ cells (Fig. 5C, yellow cells) was observed in the
PDGF-transfected glomeruli without significant infiltra-
tion of macrophages or CD45+ blood cells (Fig. 5D and
E). These cells were identified as bone marrow–derived
mesangial cells according to our previous methods [8].
Each glomerulus had a quite different yet significant
number of bone marrow–derived mesangial cells, which
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Fig. 6. Number of cells in platelet-derived growth factor (PDGF)-
transfected glomeruli of chimeric rats. (A) The number of glomeru-
lar cells was counted by staining nuclei of frozen sections with 4′, 6
diamidino-2-phenylindole (DAPI). The results are shown as mean ±
SD after 50 glomerular sections were counted. Lane a is mock-
transfected kidneys; lane b is human PDGF-B–transfected kidneys; and
lane c is human PDGF-B–transfected kidneys with the neutralization
by PDGFR/Fc. (B) The numbers of enhanced green florescent protein-
positive (EGFP+)-glomerular cells () and EGFP+Thy-1+-glomerular
cells () were counted. The results are shown as mean ± SD after 50
glomerular sections were counted. Lane a is mock-transfected kidneys;
lane b is human PDGF-B-transfected kidneys; and lane c is human
PDGF-B-transfected kidneys with the neutralization by PDGFR/Fc.
Statistical significance was analyzed by t test, and is designated by as-
terisks (∗P < 0.05, ∗∗P < 0.01).
presumably reflected the different transfection/express-
ion level of human PDGF-B among the glomeruli (Fig. 6).
When a PDGF-neutralizing molecule, PDGFR-b
ligand-binding domain fused with IgG-Fc was overex-
pressed in the skeletal muscle of the hindlimb of the
chimeric rats 24 hours prior to the introduction of human
PDGF-B, the increase of bone marrow–derived Thy-1+
cells were prevented (Figs. 6 and 7).
DISCUSSION
We demonstrated here that bone marrow–derived cells
can differentiate into mesangial-like cells in response to
PDGF-BB, retinoic acid, and collagen type IV in vitro.
These cells were identified mainly by the expression of
Thy-1 and desmin, and by the appearance. Bone marrow–
derived Thy-1++/desmin+ cells seemed more mesangial-
like because they were stellate and contracted in
response to angiotensin II. We, however, could not con-
clude that bone marrow–derived Thy-1/desmin-double
positive cells were equal to cultured mesangial cells at
least in terms of the expression level of Thy-1 (Fig. 2).
Although about half of the cultured mesangial cells ex-
press both Thy-1 and desmin (Fig. 3), most of them
seemed to be Thy-1+ but not Thy-1++ (Fig. 2). At the
present moment, we do not know the detail of what
makes the difference between Thy-1+/desmin+ cells and
Thy-1++/desmin+ cells, or how different their properties
are. Because both types of cells were observed even in
cultured mesangial cells, the expression level of Thy-1
in culture might not matter as a property of mesangial
cells. Uncharacterized cells such as fibroblasts also ex-
isted in the bone marrow culture. Probably, the expected
percentage of mesangial stem/precursor cells in the bone
marrow culture must be lower than the percentage of
Thy-1++/desmin+ cells.
We also found that PDGF-B whose local concentration
was increased by an in vivo gene transfer technique pro-
moted the integration of bone marrow–derived mesan-
gial cells in the glomeruli. These in vitro and in vivo data
strongly support our previous result that bone marrow
is a reservoir for mesangial cells [8], and highly suggest
that PDGF-BB is an important factor for the differenti-
ation. Various types of cells were produced in the differ-
entiation medium, which is reminiscent of the fact that
a single factor can induce differentiation of embryonic
stem cells in vitro but produce a heterogeneous popula-
tion [28]. Reportedly, effects of PDGF on cells seem to
be modified by environmental factors. Functions of the
PDGF-B/PDGFR-b system depend on microenviron-
ments. The function served by the PDGF-B/PDGFR-b
system in the reactive connective tissue formation is dis-
sociated from that served during development of meso-
dermal lineages [29, 30]. PDGF (1 to 25 ng/mL) is shown
to facilitate proliferation of bone marrow stromal cells,
which are expected to comprise mesenchymal stem cells
[31, 32]. However, although small yet significant amount
of PDGF must be provided by FCS, horse serum and/or
chicken embryo extract in the growth medium of our
experiments, the medium did hardly convert bone mar-
row cells into mesangial-like cells. We used 200 ng/mL
of PDGF-BB in the differentiation medium. Taking the
effect of in vivo PDGF-B overexpression into considera-
tion, we may assume that the conversion of bone marrow–
derived cells into mesangial-like cells required higher
concentration of PDGF. It is also possible that unknown
factors that are included in FCS or chicken embryo ex-
tract in the growth medium interfere with the action of
PDGF-BB.
It is not known yet whether human PDGF-B that was
overexpressed in the rat glomeruli reached the bone mar-
row and induced the recruitment of stem cells. It is rather
unlikely. Currently, we think that the following hypothesis
is more plausible. Bone marrow–derived stem cells in cir-
culation lodge in the interstitial area of the kidney. Then,
in response to PDGF-BB that is locally up-regulated,
the cells are recruited to glomeruli and are promoted to
become mesangial cells. PDGF might function both as a
chemoattractant within a short distance and as a differ-
entiation factor, which remains to be clarified. We identi-
fied bone marrow–derived mesenchymal cells in the renal
interstitium of bone marrow chimeric rats [7, 8]. Stem
cells with mesenchymal multipotency are shown to en-
ter the circulation [33]. Experiments to prove whether
functional bone marrow–derived stem cells reside in the
kidney are currently under way.
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Microenvironment mentioned above includes matrix
proteins. In this study, we fractionized bone marrow cells
by serial replating in combination with collagen types I
and IV. Collagen type IV was chosen because it is the
major matrix protein of the normal mesangium and pro-
tects cultured mesangial cells from apoptosis while col-
lagen type I that is overexpressed in diseased glomeruli
does not promote the survival of mesangial cells [34].
Differential adhesion to substratum or matrix seems to
be a useful approach to separate mesenchymal stem cells
from differentiated cells. Lee et al [24] purified cells with
mesenchymal multipotency from skeletal muscle by serial
replating onto collagen type I–coated dishes. Cells with
similar characteristics are also obtained from the bone
marrow [35]. It is premature to say that the lower affin-
ity to specific matrix proteins is a definitive trait of tissue
stem cells in vitro. Nevertheless, the trait seems to be
favorable if bone marrow–derived stem cells are re-
cruited to the glomeruli in vivo.
The most primitive hematopoietic stem cells are
CD34−. Recently, murine hematopoietic stem cells that
do not express CD34 differentiate into mesangial cells
in vivo [36]. However, it is reported that both CD34+
and CD34− stem cells can convert to CD34− and CD34+
cells, respectively [37, 38]. Another type of stem cells in
the bone marrow, mesenchymal stem cells, can give rise to
multiple mesenchymal components such as chondrocytes,
osteoblasts, and myoblasts [6]. This type of stem cells be-
longs to bone marrow stromal cells that produce various
growth factors and also interact with hematopoietic stem
cells at intercellular level [39]. Mesenchymal stem cells
make an adherent monolayer of fibroblast-like cells on
plastic dishes, and therefore look different from classical
hematopoietic stem cells. Interestingly, plastic-adherent
CD34−/low hematopoietic stem cells can produce both
CD34+ cells with hematopoietic activity and cells with
mesenchymal plasticity [40, 41]. At the present moment,
we have no data to tell what type of cells, CD34+ or
CD34−, was converted into mesangial-like cells in vitro.
Reyes and Verfaillie [42] and Jiang et al [43] have recently
established multipotent adherent cells from bone marrow
of human, mice, and rats. The cells, called multipotent
adult progenitor cells, can proliferate without senescence
in vitro and can contribute to all three germ layers in vivo,
including hematopoietic lineage. After all, it seems to be
difficult to distinguish stem cells with mesenchymal mul-
tipotency from the most primitive hematopoietic stem
cells.
The significance of all-trans retinoic acid was uncer-
tain. Basically, vitamin A plays indispensable roles for the
nephrogenesis [44], and high concentration of all-trans
retinoic acid induces the in vitro formation of pronephros
from the animal cap of Xenopus eggs [45]. All-trans
retinoic acid enhances the ex vivo maintenance of long-
term repopulating stem cells [46], and stimulates tran-
scription of PDGFR-∝ in a certain type of cells [47].
However, there was no significant change in the number
of bone marrow–derived Thy-1+ cells in the glomeruli
even when all-trans retinoic acid (10 mg/kg) was subcuta-
neously administered for 7 days from the day of the elec-
troporation (data not shown). Although endogenously
produced all-trans retinoic acid might be sufficient, we
have no answer yet.
Events of cell fusion should be considered especially
when one performs fate mapping of given cells. Y chro-
mosome fluorescent in situ hybridization (FISH) might
be useful to detect the fusion when applied in combi-
nation with cells that are simultaneously labeled with
other methods. Masuya et al [36] successfully performed
Y chromosome FISH to exclude cell fusion in their
male-to-male transplantation mice. They concluded that
hematopoietic stem cell–derived mesangial cells in vivo
are not due to fusion of two cells because only a single Y
chromosome can be detected in EGFP+ intraglomerular
cells. However, at least in rats, we failed to obtain con-
vincing signals by the combination of FISH and EGFP
staining. Instead, our data that significant number of bone
marrow–derived cells can be converted into mesangial-
like cells in vitro under the specific condition strongly
support that the generation of bone marrow–derived
mesangial (-like) cells resulted from differentiation, not
from the event of cell fusion.
CONCLUSION
We have successfully converted rat bone marrow–
derived cells into mesangial-like cells, which share sev-
eral properties with mesangial cells. Our in vitro and in
vivo data indicate that PDGF-B plays a critical role to
orchestrate the event.
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